Cingulate Achieves Manufacturing Milestone In Development Of ADHD Drug CTx-1301 In Preparation For FDA Marketing Clearance
Portfolio Pulse from Benzinga Newsdesk
Cingulate has completed twelve required registration batches for its ADHD drug CTx-1301, marking a significant milestone in its development. The company is now preparing a New Drug Application for submission to the FDA for marketing clearance.
June 25, 2024 | 1:22 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cingulate has completed twelve required registration batches for its ADHD drug CTx-1301 and is preparing a New Drug Application for FDA submission. This milestone is crucial for the company's progress towards marketing clearance.
Completing the required registration batches is a significant step towards FDA approval, which could lead to future revenue streams. This progress is likely to positively impact Cingulate's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100